Follow the GENELUX CORPORATION stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €120.4m. The latest transaction was filed on 1 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: JOHN SMITHER. The full history is free.
Analysts rate GENELUX CORPORATION Strong Buy (bullish), based on 6 analysts. Average price target: US$17.50.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
GENELUX CORPORATION 是一家在 XNAS 市场上市的公司,专注于开发用于癌症治疗的基因疗法。